Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks

To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetics of topotecan administered as a 30-min intravenous (i.v.) infusion over 5 days in combination with a 1-h i.v. infusion of ifosfamide (IF) for 3 consecutive days every 3 weeks. Patients with advanced malignan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerbusch, T, Groenewegen, G, Mathôt, R A A, Herben, V M M, ten Bokkel Huinink, W W, Swart, M, Ambaum, B, Rosing, H, Jansen, S, Voest, E E, Beijnen, J H, Schellens, J H M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409520/
https://www.ncbi.nlm.nih.gov/pubmed/15150579
http://dx.doi.org/10.1038/sj.bjc.6601861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409520/
https://www.ncbi.nlm.nih.gov/pubmed/15150579
http://dx.doi.org/10.1038/sj.bjc.6601861

Ejemplares similares